MAM
APGE

Meeder Asset Management’s Apogee Therapeutics APGE Stock Holding History

Meeder Asset Management’s Portfolio APGE Stock Details APGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-6,632
Closed -$141K – 469
2023
Q3 		$141K Buy
+6,632
New +$146K 0.01% 349

Other funds holding APGE

VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Meeder Asset Management's APGE Position: Q4 2023 in Review

Meeder Asset Management sold out of Apogee Therapeutics (APGE) in Q4 2023, closing a stake of 6,632 shares — an estimated $141K sold.

Meeder Asset Management first reported a position in APGE in Q3 2023 and held it in 1 quarter. The position peaked at $141K in Q3 2023. 85 funds tracked by Wall St. Rank hold APGE as of Q4 2023.

  • Meeder Asset Management reported no remaining Apogee Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Meeder Asset Management sold 6,632 Apogee Therapeutics shares in Q4 2023, an estimated $141K.
  • Meeder Asset Management first reported a position in Apogee Therapeutics in Q3 2023 and held it in 1 quarter.
  • Meeder Asset Management's Apogee Therapeutics position peaked at $141K in Q3 2023.
  • 85 funds tracked by Wall St. Rank held Apogee Therapeutics as of Q4 2023.

Based on Meeder Asset Management's 13F filing for Q4 2023, filed 25 Jan 2024.